Olorofim Phase 3 results show fewer kidney complications in patients with invasive aspergillosis
F2G and Shionogi's oral olorofim meets Phase 3 aspergillosis endpoint with fewer kidney adverse events. Explore the results and FDA plans.
Pharma & Biotech